News

Regional Partners Collaborate to Launch Advancing Oncology InnoVAtion QuickFire Challenge

Johnson & Johnson Innovation, in collaboration with Carilion Clinic Innovation, Verge Alliance, and Virginia Tech Corporate Research Center, is proud to launch the Advancing Oncology InnoVAtion QuickFire Challenge. Innovators from around the globe are invited to submit potential solutions aiming to transform patient outcomes in oncology in adult populations with potential applications in pediatric oncology.

Virginia is home to a growing community of more than 300 life science companies, nurtured by resources from the state and expertise from its many universities and research institutions. In 2022 alone, Virginia’s Higher Education Institutions collectively earned $382M in grant funding across 898 NIH awards.

Leveraging this innovation ecosystem, the Roanoke-Blacksburg region in Virginia is well-positioned to drive significant therapeutic advances for healthcare’s greatest challenges, including within oncology. Cancer was the second leading cause of death among adults in Virginia, claiming the lives of over 15,000 Virginians in 2020. In 2023, it is estimated that there will be 47,000 new cancer diagnoses in the state.

At Johnson & Johnson Innovation, it’s our goal to find innovative technologies that aim to deliver new approaches to detect, intercept, and treat diseases like cancer. Through this QuickFire Challenge, we are igniting innovation to transform patient outcomes in oncology not only for patients in Virginia but around the world.

The innovator(s) with the best potential solution can receive grant funding from a total pool of $300,000*, VTCRC residency for one year, which includes one lab bench and workstation, access to the global Johnson & Johnson Innovation – JLABS (JLABS) network, and mentorship from experts across The Johnson & Johnson Family of Companies (Johnson & Johnson).**

*Awardees must have a business footprint within the Roanoke-Blacksburg region of Virginia before receiving a monetary award and remain in the region for two years following receipt of the award 

**Subject to the execution of the necessary documentation and (award) agreements 

Apply at http://jji.jnj/VA by August 11, 2023.  

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin